Satellos Reports 2025 Financial Results and Highlights Recent Company Progress [Yahoo! Finance]
Satellos Bioscience Inc. (MSLE)
Company Research
Source: Yahoo! Finance
Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP, a placebo-controlled Phase 2 clinical trial of SAT-3247 in boys aged 7 to less than 10 years living with Duchenne muscular dystrophy (“Duchenne” or “DMD”) Presented initial functional outcomes from 56 days of treatment in TRAILHEAD (follow-on trial to CL-101) at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, demonstrating that grip strength improvements observed in CL-101 were maintained or improved in TRAILHEAD over an aggregate period of 9 to 13 months Reported proteomic data from CL-101 (28-day Phase 1b trial in adults with DMD) at MDA, showing reductions in established biomarkers of muscle degeneration following SAT-3247 treatment Presented validation of a Regenerative Index (“RI”) biomarker at MDA, supporting its use to quantify muscle regeneration
Show less
Read more
Impact Snapshot
Event Time:
MSLE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MSLE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MSLE alerts
High impacting Satellos Bioscience Inc. news events
Weekly update
A roundup of the hottest topics
MSLE
News
- Satellos Bioscience (MSLE) is now covered by Leerink Partners. They set an "outperform" rating and a $20.00 price target on the stock.MarketBeat
- Satellos Bioscience (MSLE) had its price target raised by HC Wainwright from $1.20 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Satellos Reports 2025 Financial Results and Highlights Recent Company ProgressGlobeNewswire
- Satellos Bioscience (MSLE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MSLE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> to "stroMarketBeat
- Satellos Bioscience (MSLE) is now covered by Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
MSLE
Sec Filings
- 3/27/26 - Form S-8
- 3/27/26 - Form 40-F
- 3/27/26 - Form 6-K
- MSLE's page on the SEC website